Clinical

Blinatumomab produced remission in high-risk patients with Ph+ B-Cell precursor acute lymphoblastic leukemia

Amgen announced that the Journal of Clinical Oncology published results from the Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of Blincyto (blinatumomab) in patients with Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia who had failed at least one second-generation or later tyrosine kinase inhibitor.

Phase III MONARCH 2 study of abemaciclib meets primary endpoint of PFS

Eli Lilly and Co. said its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival. The phase III study evaluated abemaciclib, a cyclin-dependent kinase 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer who have relapsed or progressed after endocrine therapy.